Santa Ana Bio Debuts with $168M to Develop Precision Inflammatory Medicines

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

SixPeaks Snags $110M from Versant, AZ for Drugs to Preserve Muscle and Shed Fat
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets
Startup Profiles: Upstream Bio Gets Another $200M, Kate Therapeutics Debuts with $51M
Abdera Gets $142M To Make Potent, Safe, Radioantibodies for Cancer